Jess Demaria, MD
Dermatology · Westerville, OHNPI 1154373009
Payments from drug & device makers
Across 777 payments — averaging $1046.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$458K
- Bausch Health US, LLC$154K
- Sanofi US Services Inc.$50K
- Pfizer$43K
- LEO Pharma AS$34K
- Journey Medical Corporation$24K
- plus $51K from 27 others
Across 5 payments — averaging $46,341 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nielsen Biosciences, Inc.$189K
- Bausch Health US, LLC$43K
What the payments were for
- Consulting fees$80014%
- Food & beverage$4,76582%
- Education$2735%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 464 | $457,563 |
| Bausch Health US, LLC | 9 | $153,630 |
| Sanofi US Services Inc. | 15 | $50,335 |
| Pfizer | 38 | $42,801 |
| LEO Pharma AS | 16 | $33,779 |
| Journey Medical Corporation | 4 | $24,245 |
| VYNE Pharmaceuticals Inc. | 8 | $22,893 |
| Hoffmann-la Roche Limited | 9 | $22,500 |
| AbbVie | 63 | $1,166 |
| Almirall LLC | 5 | $876 |
| E.r. Squibb & Sons, L.L.C. | 23 | $536 |
| Johnson & Johnson | 16 | $431 |
| Sun Pharmaceutical Industries Inc. | 22 | $419 |
| Lilly USA, LLC | 19 | $391 |
| Galderma Laboratories, L.p. | 7 | $314 |
| Boehringer Ingelheim | 7 | $163 |
| Regeneron Healthcare Solutions, Inc. | 7 | $135 |
| Novartis | 6 | $111 |
| Sanofi | 5 | $99 |
| Dermavant Sciences, Inc. | 3 | $93 |
| Prugen, Inc. Pharmaceuticals | 5 | $78 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $68 |
| Amgen | 4 | $58 |
| Botanix SB Inc | 2 | $52 |
| Arcutis Biotherapeutics, Inc. | 3 | $47 |
| Bristol Myers Squibb | 2 | $44 |
| UCB, Inc. | 2 | $40 |
| Genentech USA, Inc. | 2 | $35 |
| Siemens Medical Solutions USA, Inc. | 1 | $31 |
| Biofrontera Inc. | 2 | $26 |
| Organon | 2 | $21 |
| Merck | 1 | $11 |
| Mylan Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Klisyri$800
How this compares
$813,004 in reported general payments places this provider in the 95th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 32 | $190,336 |
| Metronidazole | 52 | $2,093 |
| Betamethasone Dipropionate | 35 | $1,508 |
| Clobetasol Propionate | 30 | $1,508 |
| Doxycycline Hyclate | 65 | $1,338 |
| Clindamycin Phosphate | 25 | $884 |
| Ketoconazole | 67 | $802 |
| Triamcinolone Acetonide | 102 | $795 |
| Azelaic Acid | 13 | $705 |
| Mometasone Furoate | 27 | $624 |
| Econazole Nitrate | 27 | $489 |
| Mupirocin | 80 | $464 |
| ValacyclovirValacyclovir Hcl | 36 | $213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $58 | $190,33632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 460 dermatology providers in Ohio.
Other dermatology in Westerville
- Jennifer NashWesterville$4M
- Joshua GrosshandlerWesterville$479K
- Kevin DonnellyWesterville$353K
- Matthew ZirwasBexley$7.4M
- Neil KormanCleveland$6M
- Jeffrey TraversDayton$4.7M
- Jessica KaffenbergerColumbus$3.2M
- Rocco SerraoDayton$3M
- Patrick ShannonBoardman$2M
- George DrewMarion$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.